%0 Journal Article
%T Molecular and immune pathobiology of human angiosarcoma.
%A Lim RMH
%A Lee JY
%A Kannan B
%A Ko TK
%A Chan JY
%J Biochim Biophys Acta Rev Cancer
%V 1879
%N 5
%D 2024 Jul 18
%M 39032539
%F 11.414
%R 10.1016/j.bbcan.2024.189159
%X Angiosarcoma is a rare endothelial-derived malignancy that is extremely diverse in anatomy, aetiology, molecular and immune characteristics. While novel therapeutic approaches incorporating targeted agents and immunotherapy have yielded significant improvements in patient outcomes across several cancers, their impact on angiosarcoma remains modest. Contributed by its heterogeneous nature, there is currently a lack of novel drug targets in this disease entity and no reliable biomarkers that predict response to conventional treatment. This review aims to examine the molecular and immune landscape of angiosarcoma in association with its aetiology, anatomical sites, prognosis and therapeutic options. We summarise current efforts to characterise angiosarcoma subtypes based on molecular and immune profiling. Finally, we highlight promising technologies such as single-cell spatial "omics" that may further our understanding of angiosarcoma and propose strategies that can be similarly applied for the study of other rare cancers.